Printer Friendly

MP-1, Inc. Changes Name to Phoenix Biosciences, Inc. to Reflect Company Growth.

HOLLYWOOD, Fla. -- Phoenix Biosciences, Inc. strengthens its commitment to developing treatments for HIV/AIDS

Phoenix Biosciences, Inc., focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS, announced today that it has officially changed its name from MP-1, Inc. to Phoenix Biosciences, Inc. This reflects the company's growth and its continued focus on testing its compound drug PBS119, which was developed as a unique approach for treating HIV/AIDS.

PBS119 takes a different approach than the current drugs used to treat HIV/AIDS. Instead of attacking the virus itself, this treatment uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. In preliminary pilot tests conducted by Phoenix Biosciences, PBS119 demonstrated positive results, which provided the company with the added assurance to continue with their unique approach.

"With an increased focus on HIV/AIDS, our new name Phoenix Biosciences represents a turning point for the company," said Dr. Robert Keller, Chairman, CEO and CSO of Phoenix Biosciences. "An estimated 40 million people are infected with HIV and we are committed to accelerating the process allowing us to offer a new, affordable and non-toxic treatment for HIV."

Phoenix is currently in the process of raising funds in order to conduct clinical trials. The company is determined to complete these clinical trials and gain FDA approval to begin offering patients this treatment worldwide.

About Phoenix Biosciences, Inc.

Phoenix Biosciences, Inc. is focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS in the last decade. The company has developed the compound drug PBS119 as a different approach for treating the HIV virus. This approach uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. With headquarters in Hollywood, Florida, Phoenix Biosciences, Inc. is a privately-held biotech company owned by parent company Immune Balance Technologies, LLC (IBT). In addition, IBT owns Vit-Immune, which develops, tests and markets nutritional supplements that assist in the general well-being of people and enhances the benefits of PBS119 for those suffering from chronic immune diseases including HIV/AIDS. For more information about Phoenix Biosciences, Inc. or Vit-Immune, please email pbs@robkellermd.org or visit www.robkellermd.org
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 17, 2004
Words:377
Previous Article:TIAX Chosen by DOE for Hydrogen Storage Research Project; $1.5 million project will assess hydrogen storage technologies in an effort to make...
Next Article:Telkonet Highlights Powerline Communications at 2004 NMCI Industry Symposium.


Related Articles
Soane BioSciences Renamed ACLARA BioSciences.
Soane BioSciences Renamed ACLARA BioSciences.
Phoenix Technologies Announces Immediate Server Support for the AMD Athlon MP Processor.
SPOTLIGHT ON DUCKS.
Corporate changes: the consolidation of the life/health industry continued in 2001. (Life/Health).
BD Names Vincent A. Forlenza President of BD Biosciences.
BD Announces Record Fiscal Fourth Quarter and Full Year Revenues.
Medium density fiberboard reference guide.
Phoenix Biosciences, Inc. Issued United States Patent for the Clinical Development of PBS119 For HIV/AIDS; New patent marks first step towards...
Examine Role of Amplification Technology in Diagnostics of Infectious Diseases.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters